CGRP抑制剂治疗或预防偏头痛相关的脱发信号:一项药物警戒研究
该回顾性 disproportionality 分析基于FAERS截至2021年第四季度的数据,评估CGRP抑制剂是否与脱发报告不成比例相关。结果显示,CGRP抑制剂整体及fremanezumab、erenumab、galcanezumab、eptinezumab个体均检测到脱发信号,且CGRP靶向生物制剂是主要驱动因素。
要点
- CGRP抑制剂整体与脱发报告不成比例相关(PRR 4.06;95% CI 3.88-4.25)。
- 四种CGRP抑制剂单药均检出脱发信号,其中fremanezumab的PRR最高(5.42)。
- CGRP靶向生物制剂相对于其他药物脱发信号更显著(PRR 6.11;95% CI 3.79-9.87)。
核心结论
- 基于FAERS报告,CGRP抑制剂相对于所有其他药物及某些偏头痛对照治疗存在显著脱发信号,CGRP靶向生物制剂主要驱动不成比例报告。
研究设计与样本
- 回顾性disproportionality分析,数据源为美国FDA不良事件报告系统(FAERS)截至2021年第四季度的自发报告。
- 通过计算比例报告比(PRR)及95%置信区间(CI)衡量不成比例,PRR>2.0且95%CI下限>1.0且≥3例视为阳性信号。
主要发现
- 研究期间CGRP抑制剂作为可疑药物报告了55,994例不良事件,其中脱发病例1,827例(3.26%)。
- 与FAERS中所有其他药物相比,CGRP抑制剂整体检出脱发信号(PRR 4.06;95% CI 3.88-4.25)。
- 个体药物信号:fremanezumab(PRR 5.42;95% CI 4.66-6.29)、erenumab(PRR 4.29;95% CI 4.05-4.54)、galcanezumab(PRR 4.11;95% CI 3.78-4.48)、eptinezumab(PRR 2.06;95% CI 1.25-3.40)。
- CGRP抑制剂相对于曲普坦类(PRR 12.46;95% CI 10.22-15.18)和塞来昔布(PRR 3.50;95% CI 3.19-3.83)一致显示脱发信号,但与抗惊厥药、onabotulinumtoxinA或β受体阻滞剂比较未显示。
- CGRP抑制剂类别内,生物制剂相对于其他药物检出脱发信号(PRR 6.11;95% CI 3.79-9.87)。
临床怎么用
- 临床药师在偏头痛患者使用CGRP抑制剂时应关注脱发相关主诉,尤其使用生物制剂时。
- 对出现脱发的患者,可评估CGRP抑制剂作为潜在原因,并参考PRR信号强度权衡继续治疗的必要性。
局限性
- 基于自发报告数据,存在报告偏倚和混杂因素,无法确定因果关系。
- 脱发病例定义依赖MedDRA首选术语,可能受报告质量影响。
- 需要未来观察性数据进一步明确CGRP抑制剂与真实世界新发脱发的潜在关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY OBJECTIVE: Although rarely observed in clinical trials, alopecia has been reported in migraine patients treated with calcitonin gene-related peptide (CGRP) inhibitors during the postmarketing period. This study sought to assess whether CGRP inhibitors are associated with disproportionate alopecia reporting relative to other drugs including those indicated for migraine treatment or prophylaxis in a real-world setting. DESIGN: Retrospective disproportionality analysis. DATA SOURCE: Spontaneous adverse events reported to the United States Food and Drug Administration Adverse Event Reporting System (FAERS) through the fourth quarter of 2021. MEASUREMENTS AND MAIN RESULTS: Thirteen Medical Dictionary for Regulatory Activities preferred terms were used to define alopecia cases in FAERS. Disproportionality was measured by calculating proportional reporting ratios (PRR) and 95% confidence intervals (CI). A PRR >2.0 with a lower 95% CI >1.0 and ≥3 cases was considered a positive signal. During the study period, CGRP inhibitors were reported as suspect products in 55,994 adverse events including 1827 (3.26%) alopecia cases. Compared with all other drugs across FAERS, alopecia signals were detected for the collective CGRP inhibitor class (PRR 4.06; 95% CI 3.88-4.25) and fremanezumab (PRR 5.42; 95% CI 4.66-6.29), erenumab (PRR 4.29; 95% CI 4.05-4.54), galcanezumab (PRR 4.11; 95% CI 3.78-4.48), and eptinezumab (PRR 2.06; 95% CI 1.25-3.40) individually. CGRP inhibitors were consistently associated with alopecia signals relative to triptans (PRR 12.46; 95% CI 10.22-15.18) and celecoxib (PRR 3.50; 95% CI 3.19-3.83), but not in comparison with anticonvulsants, onabotulinumtoxinA, or beta-blockers across analyses. Within the CGRP inhibitor class, an alopecia signal was observed for biologics relative to drugs (PRR 6.11; 95% CI 3.79-9.87). CONCLUSION: Significant alopecia signals were identified for CGRP inhibitors relative to all other drugs and certain comparator migraine therapies based on adverse events reported to FAERS, with CGRP-targeting biologics primarily driving disproportionate reporting. Future observational data will be necessary to better characterize the potential association between real-world use of CGRP inhibitors and incident alopecia in patients with migraine.
引用
- Woods RH. Alopecia signals associated with calcitonin gene-related peptide inhibitors in the treatment or prophylaxis of migraine: A pharmacovigilance study. Pharmacotherapy. 2022. PMID: 35975575. doi:10.1002/phar.2725
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。